Tenofovir DF (HIV)

Tenofovir Disoproxil Fumarate (TDF) is an important HIV drug highly recommended by the World Health Organisation. Challenges to the patents on this drug have been filed in India and the US. Gilead Sciences, the US patent holder of TDF, has issued voluntary licenses to several Indian generic producers. The Indian Patent Office has rejected the Indian TDF patents based on oppositions by an Indian generic supplier. Read the decisions HERE, and read more about the global challenges HERE.


The following I-MAK document is a background of the TDF patent opposition

 Summary of the Indian patent opposition [pdf]


I-MAK Patent Challenge documents

Opposition on Tenofovir Disoproxil [pdf]

Opposition on Tenofovir Disoproxil Fumarate [pdf]

Observation on Tenofovir Disoproxil Fumarate [Chinese pdf]


TDF Voluntary License 

I-MAK memorandum on TDF voluntary licenses [pdf


Links to Selected Media/Listserve clippings on Indian TDF challenge

"India Overturns HIV Drug Patents", Financial Times

"Saving Lives? Its Patently Obvious", Guardian

"India refuses patent protection for AIDS drug of US company", Business Standard

"India Rejects Patent Claims on 2 HIV Drugs", the Hindu

"India says no to HIV drug Patents", Nature

"AIDS Groups in India Sue to Halt Patent for U.S. Drug", New York Times

"Gilead's AIDS Drug Patent faces patient networks' opposition", Hindu Business Line

"No Patent Cry for HIV Lifeline", The Telegraph

Question and response on TDF, Commons Law listserve

"Gilead pushed for patent for HIV drug in India", Reuters

"MSF Supports Opposition to Gilead's Tenofovir Patent Application in India", MSF 

"A look at drug firm's story of supplying AIDS patients", SF Chronicle 

"Drug firms seek to stop generic HIV treatment", The Guardian 


Links to other patent challenges and competition cases

PUBPAT press note on US re-examination

CP Tech FTC filing


I-MAK Pricing

Analysis of TDF and FTC Sales and Pricing, September 2012